Topics

Clovis Oncology's Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

04:43 EDT 11 Oct 2019 | Pharmafile

NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the drug will now be made available immediately via the Cancer Drugs Fund (CDF) for women in England with relapsed ovarian, fallopian tube or peritoneal cancer, that has responded to platinum-based chemotherapy.

The UK watchdog originally turned down the therapy due to concerns over the certainty of the data submitted, as well as over cost-effectiveness, based on the price put forward by Clovis.

read more

Original Article: Clovis Oncology's Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer

NEXT ARTICLE

More From BioPortfolio on "Clovis Oncology's Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...